NCT07007559View on ClinicalTrials.gov

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

Breast Cancer, Metastatic

Interventions

DRUG

Evorpacept (ALX148)

IV infusion

DRUG

Trastuzumab

IV infusion

DRUG

Paclitaxel

IV infusion

DRUG

Capecitabine

Oral administration

DRUG

Eribulin

IV infusion

DRUG

Gemcitabine

IV infusion

DRUG

Vinorelbine

IV infusion

Trial Locations (1)

44718

RECRUITING

Gabrail Cancer Center, Canton

Sponsors

Lead Sponsor

ALX Oncology Inc.

All Listed Sponsors

lead

ALX Oncology Inc.

INDUSTRY